Irinotecan plus oxaliplatin: A promising combination for advanced colorectal cancer

Clinical colorectal cancer

Volumn 1, Issue 3, 2001, Pages 149-153

  Wasserman, Ernesto ^a,b   Sutherland, William ^c   Cvitkovic, Esteban ^c  

^a Cvitkovic and Associates Consultants   (Argentina)

^b Servicio de Oncologia   (Argentina)

^c Cvitkovic et Associes Consultants   (France)

Author keywords

5 Fluorouracil; Colorectal cancer; Folinic acid; Oxaliplatin; Salvage chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN; OXALIPLATIN; PLATINUM COMPLEX;

CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ADMINISTRATION; DRUG POTENTIATION; HUMAN; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; HUMANS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 0035522658     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2001.n.015     Document Type: Review

References (24)

1. CG Moertel Chemotherapy for colorectal cancer N Engl J Med 330 1994 1136 1142
2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial J Clin Oncol 10 1992 904 911
3. W Scheithauer H Rosen GV Kornek Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 306 1993 752 755
4. T Conroy P Rauch F Guillemin [Quality of life in patients with colorectal cancer] Gastroenterol Clin Biol 23 1999 489 501
5. D Cunningham S Pyrhonen RD James Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 352 1998 1413 1418
6. P Rougier E Van Cutsem E Bajetta Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer Lancet 352 1998 1407 1412
7. JY Douillard D Cunningham AD Roth Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 2000 1041 1047
8. LB Saltz JV Cox C Blanke Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 2000 905 914
9. S Giacchetti B Perpoint R Zidani Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracilleucovorin as first-line treatment of metastatic colorectal cancer J Clin Oncol 18 2000 136 147
10. A de Gramont A Figer M Seymour Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2000 2938 2947
11. N Zeghari-Squalli E Raymond E Cvitkovic Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN- 38 and the diaminocyclohexane platinum derivative oxaliplatin Clin Cancer Res 5 1999 1189 1196
12. F Goldwasser L Bozec N Zeghari-Squalli Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line Anticancer Drugs 10 1999 195 201
13. E Raymond S Djelloul C Buquet-Fagot Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anticancer Drugs 8 1997 876 885
14. N Zeghari-Squalli J Misset E Cvitkovic Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin Clin Cancer Res 5 1999 1189 1196
15. E Wasserman C Cuvier F Lokiec Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics J Clin Oncol 17 1999 1751 1759
16. F Goldwasser M Gross-Goupil JM Tigaud Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients Ann Oncol 11 2000 1463 1470
17. N Kemeny W Tong J Stockman Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer Proc Am Soc Clin Oncol 19 2000 245a (Abstract #948).
18. W Scheithauer GV Kornek M Raderer Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer J Clin Oncol 17 1999 902 906
19. P Rougier D Lepille JY Douillard Final results of a randomised phase II study of three combinations: CPT-11 + LV5FU2, LOHP + LV5FU2, and CPT-11 + LOHP in 5-FU resistant advanced colorectal cancer (ACRC) Proc Am Soc Clin Oncol 20 2001 142a (Abstract #566).
20. B Yves M Mousseau E Gamelin Final results of CPT-11 and L-OHP combination versus alternated combination of LV5FU2 + CPT-11/LV5FU2 + LOHP in 5FU resistant advanced colorectal cancer (ACRC) Proc Am Soc Clin Oncol 19 2000 252a (Abstract #978).
21. R Morton R Goldberg D Sargent Oxaliplatin (OXAL) or CPT- 11 combined with 5FU/leucovorin (LV) in advanced colorectal cancer (CRC): an NCCTG/CALGB study Proc Am Soc Clin Oncol 20 2001 125a (Abstract #495).
22. ML Rothenberg NJ Meropol EA Poplin Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel J Clin Oncol 19 2001 3801 3807
23. F Lerebours P Cottu H Hocini Oxaliplatin (OXA), irinotecan (CPT11), and 4-day continuous infusion 5-fluorouracil (CIVFU) every three weeks (Q3W): A phase I study in advanced gastrointestinal tumors Proc Am Soc Clin Oncol 19 2000 313a (Abstract #1237).
24. T Conroy J-F Seitz G Capodano Phase I study of triple combination of oxaliplatin + irinotecan + LV5FU2 in patients with metastatic solid tumors Proc Am Soc Clin Oncol 19 2000 236a (Abstract #921G).